Recent Finacing
Recent Raise
FogPharma develops Helicon hyperstabilized α‑helical, cell‑penetrating peptides using directed evolution, helix‑stabilization chemistry, high‑throughput optimization and AI-enabled structure-based discovery to target intracellular, previously undruggable proteins; advancing β‑catenin clinical program.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
